tiaprofenic acid ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory agents, ibuprofen derivatives 2652 33005-95-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tiaprofenic acid
  • (RS)-Tiaprofenic acid
  • (+/-)-Tiaprofenic acid
  • tiaprofen
  • Molecular weight: 260.31
  • Formula: C14H12O3S
  • CLOGP: 2.54
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 54.37
  • ALOGS: -3.91
  • ROTB: 4

Drug dosage:

DoseUnitRoute
0.60 g O
0.60 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 38.42 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 100 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.08 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.62 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.10 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,BTK,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK7,MAPKAPK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TEK 22
kinase-selectivity-class ACVR2B,AXL,EIF2AK3,GRK2,MAP2K6 5
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aspirin-exacerbated respiratory disease 58.85 47.47 9 625 681 90627132

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hand deformity 292.60 227.75 52 754 3716 42616813
Musculoskeletal discomfort 256.26 227.75 54 752 9422 42611107
Limb discomfort 229.31 227.75 52 754 12715 42607814

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Musculoskeletal discomfort 126.59 43.68 32 1050 23506 110564711
Limb discomfort 100.36 43.68 30 1052 40824 110547393
Localised infection 98.81 43.68 30 1052 43018 110545199
Gait inability 65.10 43.68 30 1052 136346 110451871
Liver disorder 63.89 43.68 30 1052 142213 110446004
Aspirin-exacerbated respiratory disease 52.95 43.68 9 1073 939 110587278
Shoulder operation 52.76 43.68 11 1071 3434 110584783
Therapeutic product effect decreased 48.64 43.68 30 1052 244286 110343931

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01AE11 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Propionic acid derivatives
MeSH PA D000700 Analgesics
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018501 Antirheumatic Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D018712 Analgesics, Non-Narcotic
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drug
CHEBI has role CHEBI:88188 drug allergen

Related Drugs by ATC class:

M01AE Propionic acid derivatives 21 drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pain indication 22253000
Rheumatoid arthritis indication 69896004 DOID:7148
Osteoarthritis indication 396275006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.82 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prostaglandin G/H synthase 2 Enzyme INHIBITOR IC50 7.10 WOMBAT-PK SCIENTIFIC LITERATURE
Prostaglandin G/H synthase 1 Enzyme INHIBITOR IC50 5.90 WOMBAT-PK SCIENTIFIC LITERATURE

External reference:

IDSource
D01325 KEGG_DRUG
C0076653 UMLSCUI
CHEBI:32221 CHEBI
CHEMBL365795 ChEMBL_ID
DB01600 DRUGBANK_ID
C021270 MESH_SUPPLEMENTAL_RECORD_UI
5468 PUBCHEM_CID
3320 INN_ID
1LS1T6R34C UNII
38253 RXNORM
003468 NDDF
329889002 SNOMEDCT_US
395902007 SNOMEDCT_US

Pharmaceutical products:

None